CHF Solutions System To Be Used In JAHVH Study After Final Nod
Zacks Investment Research | Oct 13, 2019 09:35PM ET
CHF Solutions (NASDAQ:CHFS) announced that Tampa, FL-based James A. Haley Veterans’ Hospital and Clinics (JAHVH) received the Institutional Review Board’s nod to start an outpatient study, using the Aquadex FlexFlow system (ultrafiltration therapy) to help manage fluid overload in patients suffering from heart failure.
This came after CHF Solutions gained a blanket purchase agreement in 2018 for up to $6.5 million from the United States Department of Veterans Affairs to supply Aquadex FlexFlow consoles and blood circuit sets to the James A. Haley Department of Veterans Affairs Medical Center in Tampa (Tampa VAMC). The agreement allowed the company to supply ultrafiltration therapy to VAMC. The contract was signed for five years.
The company claims that it is the first study to be conducted exclusively through the United States Veterans Administration. With the approval, CHF Solutions plans to consolidate position in the global ultrafiltration therapy market.
Few Words About Aquadex FlexFlow System
The Aquadex FlexFlow system is a method of removing surplus fluid in patients suffering from fluid overload. Per the company, it is a clinically proven treatment, which is safe and effective.
The system is applicable for temporary (up to eight hours) as well as extended (longer than 8 hours) ultrafiltration treatment of patients with fluid overload.
Significance of the Approval
Management of JAHVH is upbeat about the nod as it will allow it to provide better care to Veterans suffering from fluid overload, using ultrafiltration therapy in an outpatient setting.
Per the current treatment options available, patients suffering from heart failure, with fluid overload, are re-admitted into the hospital, which places a heavy economic burden on the healthcare system. With the improved treatment option being made available, it is expected to improve the quality of life while reducing costs.
Industry Prospects
Per a report by Original post
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.